Strata Oncology
The company said the results highlight precision oncology implementation challenges and its test's ability to help overcome these issues.
Strata Oncology Raises $90M in Series C Financing
The firm said it will use the proceeds to accelerate development of its MRD assay for early-stage cancers and its treatment selection tests for solid tumors.
In Brief This Week: DiaSorin, Cue Health, Avacta, Pandemic Response Lab, TruDiagnostic, and More
News items for the in vitro diagnostics industry for the week of July 12, 2021.
Strata Oncology Receives Medicare Coverage for NGS Test
The test assesses multiple factors, including single-/multi-nucleotide variants, short insertions and deletions, and microsatellite instability status.
Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor
Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.